FDA product code OYX: Bcr/Abl1 Monitoring Test
OYX is the FDA product code for bcr/abl1 monitoring test. It is a Class II device, regulated under 21 CFR 866.6060 and reviewed by the Pathology panel. FDA has cleared 5 510(k) submissions under OYX, 2 in the last five years, from 5 different applicants. The average 510(k) review took 262 days (median 254); 349 days on average over the last three years. 1 De Novo request was granted under it. FDA has posted 3 recalls for OYX devices, 3 initiated in the last five years.
Definition
A BCR/ABL1 Monitoring Test is a quantitative in vitro diagnostic device used to monitor the BCR/ABL1 to ABL1 ratio by reverse-transcriptase quantitative polymerase chain reaction (RQ-PCR) on whole blood or bone marrow of diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) patients expressing BCR-ABL1 fusion transcripts such as e13a2 and/or e14a2. It is intended for use during monitoring of treatment response by reporting results on the international scale (%IS) and as log molecular reduction (MR) value.
Classification
| Field | Value |
|---|---|
| Device name | Bcr/Abl1 Monitoring Test |
| Device class | Class II |
| Regulation | 21 CFR 866.6060 |
| Review panel | PA — Pathology |
| Medical specialty | Medical Genetics |
| Premarket route | 510(k) |
510(k) clearances per year for OYX
| Year | Clearances | Avg. review days |
|---|---|---|
| 2017 | 1 | 39 |
| 2019 | 2 | 244 |
| 2023 | 1 | 434 |
| 2026 | 1 | 349 |
Compare with all 510(k) review times · Search every OYX clearance
Top OYX applicants
| Applicant | Clearances | Latest |
|---|---|---|
| Suzhou Precigenome, Ltd. Co; | 1 | 2026-07-02 |
| Suzhou Sniper Medical Technologies Co., Ltd. | 1 | 2023-09-05 |
| Cepheid | 1 | 2019-09-27 |
| Bio-Rad Laboratories, Inc. | 1 | 2019-02-13 |
| Molecularmd Corporation | 1 | 2017-12-22 |
Most recent OYX clearances
| 510(k) | Applicant | Device | Decision date | Review days |
|---|---|---|---|---|
| K252243 | Suzhou Precigenome, Ltd. Co; | Fastplex BCR-ABL (p210) %IS digital PCR Kit | 2026-07-02 | 349 |
| K221869 | Suzhou Sniper Medical Technologies Co., Ltd. | BCR-ABL1 (p210) % IS Kit (Digital PCR Method) | 2023-09-05 | 434 |
| K190076 | Cepheid | Xpert BCR-ABL Ultra, GeneXpert Dx System, GeneXpert Infinity-48s and GeneXpert Infinity-80 Systems | 2019-09-27 | 254 |
| K181661 | Bio-Rad Laboratories, Inc. | QXDx BCR-ABL %IS Kit for use on the QXDx AutoDG ddPCR System | 2019-02-13 | 233 |
| K173492 | Molecularmd Corporation | MRDx BCR-ABL Test, MRDx BCR-ABL Test Software | 2017-12-22 | 39 |
Recalls for OYX devices
3 product recalls in 2 recall events; 3 initiated in the last five years and 3 still open. Most recent: 2025-10-30.
| Year | Recalls |
|---|---|
| 2024 | 1 |
| 2025 | 2 |
Frequently asked questions
What is FDA product code OYX?
OYX is the FDA product code for bcr/abl1 monitoring test. It is a Class II device, regulated under 21 CFR 866.6060 and reviewed by the Pathology panel.
What device class is OYX?
Class II, regulation 21 CFR 866.6060. Typical premarket route: 510(k).
How long does a 510(k) take for product code OYX?
Across 5 cleared submissions the average was 262 days from receipt to decision (median 254).
Which companies have the most OYX clearances?
Suzhou Precigenome, Ltd. Co; (1); Suzhou Sniper Medical Technologies Co., Ltd. (1); Cepheid (1); Bio-Rad Laboratories, Inc. (1); Molecularmd Corporation (1).
Have OYX devices been recalled?
Yes: 3 product recalls across 2 recall events; the most recent began 2025-10-30.
Next steps
- Run an FDA pathway report with predicate devices for product code OYX
- Run a recall and safety report across every OYX manufacturer
- Watch product code OYX for new clearances and recalls
Compiled by Caduvo from public U.S. FDA records. Applicant names are shown as FDA records them. Review days run from FDA receipt to decision. Not reviewed or endorsed by FDA. Not regulatory advice. Report an error. Data and corrections policy.
All Pathology product codes · FDA product code lookup · 510(k) database search · 510(k) review times